» Articles » PMID: 37894139

Estimated Incidence of Symptomatic Lyme Borreliosis Cases in Lublin, Poland in 2021

Overview
Journal Microorganisms
Specialty Microbiology
Date 2023 Oct 28
PMID 37894139
Authors
Affiliations
Soon will be listed here.
Abstract

Lyme borreliosis (LB), the most common tick-borne disease in Europe, is endemic to Poland. Despite public health surveillance with mandatory reporting of LB cases by physicians and laboratories, many symptomatic LB cases are not included in surveillance in Poland. We estimated the extent of the under-ascertainment of symptomatic LB cases via surveillance in the Polish province of Lublin to better understand Poland's LB burden. The number of incident symptomatic LB cases in Lublin in 2010 was estimated from two seroprevalence studies conducted among adults in Lublin, as well as estimates of the proportion of asymptomatic LB cases and the duration of LB antibody persistence. The estimated number of incident symptomatic LB cases was compared to the number of surveillance-reported cases in Lublin to derive an under-ascertainment multiplier. This multiplier was applied to the number of surveillance-reported cases in 2021 to estimate the number and population-based incidence of symptomatic LB cases in Lublin in 2021. We estimate that there are 5.9 symptomatic LB cases for every surveillance-reported LB case in Lublin. Adjusting for under-ascertainment, the estimated number of symptomatic LB cases in Lublin in 2021 was 6204 (population-based incidence: 467.6/100,000). After adjustment for under-ascertainment, the incidence of symptomatic LB in Lublin, Poland, is high.

Citing Articles

Using Catalytic Models to Interpret Age-Stratified Lyme Borreliosis Seroprevalence Data: Can This Approach Help Provide Insight into the Full Extent of Human Infection Occurring at the Population Level?.

Vyse A, Colby E Microorganisms. 2025; 12(12.

PMID: 39770840 PMC: 11678136. DOI: 10.3390/microorganisms12122638.


High Prevalence of Borrelia burgdorferi Antibodies in Jaworzno, Poland: A Retrospective Study Revealing Endemic Lyme Borreliosis.

Kolezynska B, Solarz K, Wieczorek W, Sagan D, Boron D, Staszkiewicz R Med Sci Monit. 2024; 30:e943203.

PMID: 38327041 PMC: 10863337. DOI: 10.12659/MSM.943203.

References
1.
Chmielewska-Badora J, Moniuszko A, Zukiewicz-Sobczak W, Zwolinski J, Piatek J, Pancewicz S . Serological survey in persons occupationally exposed to tick-borne pathogens in cases of co-infections with Borrelia burgdorferi, Anaplasma phagocytophilum, Bartonella spp. and Babesia microti. Ann Agric Environ Med. 2012; 19(2):271-4. View

2.
Bezay N, Hochreiter R, Kadlecek V, Wressnigg N, Larcher-Senn J, Klingler A . Safety and immunogenicity of a novel multivalent OspA-based vaccine candidate against Lyme borreliosis: a randomised, phase 1 study in healthy adults. Lancet Infect Dis. 2023; 23(10):1186-1196. DOI: 10.1016/S1473-3099(23)00210-4. View

3.
Wojciechowska-Koszko I, Mnichowska-Polanowska M, Kwiatkowski P, Roszkowska P, Sienkiewicz M, Dolegowska B . Immunoreactivity of Polish Lyme Disease Patient Sera to Specific Antigens-Part 1. Diagnostics (Basel). 2021; 11(11). PMC: 8625222. DOI: 10.3390/diagnostics11112157. View

4.
Zbrzezniak J, Paradowska-Stankiewicz I . Lyme disease in Poland in 2020. Przegl Epidemiol. 2022; 76(3). DOI: 10.32394/pe.76.36. View

5.
Marques A, Strle F, Wormser G . Comparison of Lyme Disease in the United States and Europe. Emerg Infect Dis. 2021; 27(8):2017-2024. PMC: 8314816. DOI: 10.3201/eid2708.204763. View